2024
Charting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification
Jain A, Morris M, Berardi D, Arora T, Domingo-Almenara X, Paty P, Rattray N, Kerekes D, Lu L, Khan S, Johnson C. Charting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification. Molecular Cancer 2024, 23: 211. PMID: 39342363, PMCID: PMC11438248, DOI: 10.1186/s12943-024-02133-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorColorectal NeoplasmsFemaleHumansMaleMetabolomeMetabolomicsMiddle AgedRectumConceptsRectal cancerNormal mucosaMetabolite abundancePatient-matched tumorTumor-specific metabolitesMetabolic heterogeneityPatient survivalRectosigmoid colonSigmoid colonAnatomic subsitePatient-matched normal mucosaTransverse colonMetabolomic profilesAscending colonCRC biomarkersMetabolome DatabaseDescending colonMetabolite changesLeft-sidedRight-sidedColorectumRisk factorsMetabolome mapCancerTumor
2020
Sex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype
Cai Y, Rattray NJW, Zhang Q, Mironova V, Santos-Neto A, Hsu KS, Rattray Z, Cross JR, Zhang Y, Paty PB, Khan SA, Johnson CH. Sex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype. Scientific Reports 2020, 10: 4905. PMID: 32184446, PMCID: PMC7078199, DOI: 10.1038/s41598-020-61851-0.Peer-Reviewed Original ResearchConceptsRight-sided colon cancerColorectal cancerCRC patientsColon cancer metabolismPoor clinical outcomePatient colon tumorsAsparagine synthetase expressionNovel subphenotypesClinical outcomesAmino acid uptakePoor survivalLower incidenceAnatomic locationHigh incidenceTherapeutic targetColon cancerCancer Genomic AtlasClinical importanceColon tumorsTumor progressionAberrant metabolismNormal tissuesPatientsSubphenotypesAcid uptake
2016
EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer
Khan SA, Zeng Z, Shia J, Paty PB. EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. Pathology & Oncology Research 2016, 23: 673-677. PMID: 28025786, PMCID: PMC5451302, DOI: 10.1007/s12253-016-0166-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiomarkers, TumorCamptothecinCetuximabColorectal NeoplasmsDNA Mutational AnalysisErbB ReceptorsFemaleGene AmplificationGenes, p53HumansIrinotecanMaleMiddle AgedMutationRas ProteinsConceptsCombination biologic therapyMetastatic colorectal cancerIrinotecan-refractory colorectal cancerRefractory colorectal cancerColorectal cancerEGFR gene amplificationBiologic therapyKRAS mutationsIrinotecan-refractory metastatic colorectal cancerRefractory metastatic colorectal cancerCombination Targeted TherapyGene amplificationPhase II trialEGFR copy numberII trialPredictive biomarkersPredictive markerTargeted therapyTreatment responseBRAF mutationsBevacizumabPatientsCetuximabTumor tissueTherapyColorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients
Khan SA, Morris M, Idrees K, Gimbel MI, Rosenberg S, Zeng Z, Li F, Gan G, Shia J, LaQuaglia MP, Paty PB. Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients. Journal Of Pediatric Surgery 2016, 51: 1812-1817. PMID: 27558481, PMCID: PMC5312708, DOI: 10.1016/j.jpedsurg.2016.07.015.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdolescentAdultAge of OnsetAgedAged, 80 and overBiomarkers, TumorChildColorectal NeoplasmsDNA Mismatch RepairDNA Mutational AnalysisDNA, NeoplasmFemaleHumansMaleMicrosatellite InstabilityMiddle AgedMutationNeoplasm StagingRetrospective StudiesSurvival RateUnited StatesYoung AdultConceptsOnset colorectal cancerEarly-onset colorectal cancerAdult-onset patientsColorectal cancerEarly age onsetPoor prognosisMicrosatellite instabilityOnset patientsClinical dataEarly-age onset colorectal cancerMLH1/PMS2 lossAdult colorectal cancerAdult CRC patientsAdvanced stage presentationMismatch repair expressionHigh-grade cancerAge 30 yearsSpecific genetic subtypesCRC patientsFavorable survivalPMS2 lossGrade cancerBRAF mutationsTumor markersBRAFV600E mutation
2010
Improved Testing for Microsatellite Instability in Colorectal Cancer Using a Simplified 3-Marker Assay
Esemuede I, Forslund A, Khan SA, Qin LX, Gimbel MI, Nash GM, Zeng Z, Rosenberg S, Shia J, Barany F, Paty PB. Improved Testing for Microsatellite Instability in Colorectal Cancer Using a Simplified 3-Marker Assay. Annals Of Surgical Oncology 2010, 17: 3370-3378. PMID: 20703819, PMCID: PMC3269820, DOI: 10.1245/s10434-010-1147-4.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdolescentAdultAgedAged, 80 and overBiological AssayBiomarkers, TumorColorectal NeoplasmsComparative Genomic HybridizationDNA RepairDNA Repair EnzymesFemaleFollow-Up StudiesGenetic TestingGerm-Line MutationHumansLymphatic MetastasisMaleMicrosatellite InstabilityMicrosatellite RepeatsMiddle AgedOligonucleotide Array Sequence AnalysisPrognosisProspective StudiesSurvival RateYoung AdultConceptsHereditary nonpolyposis colorectal cancerColorectal cancerMicrosatellite instabilityMSI testingMSI tumorsMismatch repair protein lossBackgroundIn colorectal cancerDisease-specific survivalPredictive scoring systemNonpolyposis colorectal cancerMore BRAF mutationsDefective DNA mismatch repairNCI criteriaFavorable prognosisFavorable survivalKRAS mutationsBRAF mutationsMSI statusDistinct phenotypic propertiesScoring systemCancerValuable markerMSS cancersMethodsDNA samplesProtein loss